Our name, Alithea, is inspired by the Ancient Greek word αλήθεια (alḗtheia), meaning “truth” — and more deeply, “unconcealedness,” the revealing of what was hidden.
We bring this concept to life by uncovering hidden biological signals in transcriptomics data to enable breakthrough discoveries.
“At Alithea Genomics, we are committed to developing solutions that streamline and simplify the generation of big RNA data, which we believe will constitute the foundation of tomorrow's research and medicine.”
Riccardo Dainese
CCO and Co-founder
Daniel Alpern
CSO and Co-founder
Alithea Genomics aims to solve one of the biggest bottlenecks in modern industrial discovery: generating the massive, high-quality transcriptomic datasets required for more scalable compound screens, more robust AI-driven discovery, and better predictive power to derisk pipelines.
We believe the future of biological discovery depends on high-throughput, large-scale transcriptomic data. Our RNA-seq-based technologies give pharmaceutical, agritech, cosmetics, and academic teams the tools to better understand drug responses, engineer more resilient crops, and develop safer ingredients by generating thousands to millions of real gene expression profiles in a single experiment.
Our story began with BRB-seq, a bulk RNA barcoding and sequencing method that introduced early sample indexing and pooling. By moving barcoding upstream, BRB-seq made it possible to prepare libraries for many samples in a single workflow, significantly reducing cost and hands-on time for bulk RNA-seq.
Building on this foundation, we created the MERCURIUS™ platform family. MERCURIUS™ DRUG-seq brings plate-based, extraction-free RNA-seq to high-throughput compound screening. MERCURIUS™ BRB-seq evolved into robust kits for scalable bulk transcriptomics across many sample types. MERCURIUS™ FLASH-seq extends these principles to highly sensitive, plate-based single-cell and low-input full-length RNA-seq.
Today, Alithea Genomics collaborates with leading pharma, CROs, agritech and cosmetics companies, as well as core facilities and academic labs worldwide. Our technologies power workflows that utilize from 96-well plates to 1,536-well plates, helping you run transcriptomic studies at the scale your questions demand.
We take responsible consumption and production seriously across every part of our business, from how we design workflows to how we ship products. By enabling high-throughput, plate-based RNA-seq with fewer consumables and fewer runs, our technologies help companies move toward their Scope 3 sustainability goals, reducing plastic waste and CO₂ emissions by up to 95% compared with standard RNA-seq practices.
LAUSANNE, Switzerland–(BUSINESS WIRE)–Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of its seed financing round…
Cambridge, UK, and Lausanne, Switzerland, 05 November 2025: SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions,…
Lausanne, Switzerland and Frederick, MD – September 25, 2025 – Alithea Genomics, a leader in next-generation transcriptomic solutions, today announced the commercial launch of MERCURIUS™…
Lausanne, Switzerland and Frederick, MD – June 19, 2025 – Alithea Genomics, a pioneering biotech company based in Switzerland and the USA specializing in high-throughput…
Tell us about your project and we will help you find the right approach.
